Christopher Liu
Stock Analyst at LUCID CAPITAL MARKETS
(2.71)
# 2,082
Out of 4,981 analysts
6
Total ratings
66.67%
Success rate
20.96%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Christopher Liu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GNLX Genelux | Initiates: Buy | $10 | $3.95 | +153.16% | 1 | Jul 21, 2025 | |
| RLAY Relay Therapeutics | Maintains: Outperform | $19 → $18 | $3.99 | +351.13% | 1 | Dec 4, 2024 | |
| IDYA IDEAYA Biosciences | Downgrades: Market Perform | $41 → $27 | $24.63 | +9.62% | 2 | Nov 5, 2024 | |
| NUVL Nuvalent | Initiates: Market Perform | $42 | $80.54 | -47.85% | 1 | Aug 8, 2023 | |
| EXEL Exelixis | Initiates: Market Perform | $18 | $39.15 | -54.02% | 1 | Aug 8, 2023 |
Genelux
Jul 21, 2025
Initiates: Buy
Price Target: $10
Current: $3.95
Upside: +153.16%
Relay Therapeutics
Dec 4, 2024
Maintains: Outperform
Price Target: $19 → $18
Current: $3.99
Upside: +351.13%
IDEAYA Biosciences
Nov 5, 2024
Downgrades: Market Perform
Price Target: $41 → $27
Current: $24.63
Upside: +9.62%
Nuvalent
Aug 8, 2023
Initiates: Market Perform
Price Target: $42
Current: $80.54
Upside: -47.85%
Exelixis
Aug 8, 2023
Initiates: Market Perform
Price Target: $18
Current: $39.15
Upside: -54.02%